Predominance of human immunodeficiency virus type 2 subtype B in Abidjan, Ivory Coast. NLM AIDSLINE Important note: Information in this article was accurate in 1999. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Predominance of human immunodeficiency virus type 2 subtype B in Abidjan, Ivory Coast.

AIDS Res Hum Retroviruses. 1999 Apr 10;15(6):603-8. Unique Identifier : AIDSLINE MED/99236727
Pieniazek D; Ellenberger D; Janini LM; Ramos AC; Nkengasong J; Sassan-Morokro M; Hu DJ; Coulibally IM; Ekpini E; Bandea C; Tanuri A; Greenberg AE; Wiktor SZ; Rayfield MA; Division of AIDS, STD, and TB Laboratory Research, National; Centers for Infectious Diseases, Centers for Disease Control and; Prevention, Atlanta, Georgia 30333, USA. dxp1@cdc.gov

Abstract: We analyzed the genetic variability and phylogenetic relationships among 28 HIV-2 strains collected from patients enrolled in an HIV epidemiologic study in Abidjan, Ivory Coast, during 1995-1996. Although both subtype A (n = 8; 29%) and subtype B (n = 20; 71%) were present in this sampling, the majority of infections were caused by subtype B viruses. These findings contrasted with the reported predominance of HIV-2 subtype A in other African countries. The broad genetic diversity identified among protease gene sequences for HIV-2 subtype A (6%; range 3-15%) and subtype B (7%; range, 2-12%), and their presence in Abidjan during the 1980s, document a long coexistence of two viral subtypes in Ivory Coast. Our data indicate that viruses of subtypes A and B have contributed to the HIV-2 epidemic in Ivory Coast.
Keywords: JOURNAL ARTICLE Adolescence Adult Cote d'Ivoire/EPIDEMIOLOGY Female Genes, gag Human HIV Infections/EPIDEMIOLOGY/IMMUNOLOGY/*VIROLOGY HIV-2/CLASSIFICATION/*GENETICS Male Middle AgeKWDjournalarticleadolescenceadultcoted'ivoire/epidemiologyfemalegenes,gaghumanhivinfections/epidemiology/immunology/KWDvirologyhiv-2/classification/KWDgeneticsmalemiddleage
990930
A9991323

Copyright © 1999 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1999. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1999. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .